Literature DB >> 12769633

Targeting the JNK pathway for therapeutic benefit in CNS disease.

Donna Bozyczko-Coyne1, Michael S Saporito, Robert L Hudkins.   

Abstract

The c-Jun N-terminal Kinase (JNK) pathway leading to c-Jun phosphorylation plays a causal role in apoptosis of isolated primary embryonic neurons and of multiple neuronal cell lines following a wide variety of stimuli. Activation of this pathway may also contribute to the neuronal atrophy and death that is associated with neurodegenerative pathological conditions including Alzheimer's, Parkinson's, Huntington's Diseases and stroke. Here, the data that providelinks between the activation of the JNK pathway and its potential to play an operative role in CNS disease are reviewed. Also included is the progress on development of inhibitors targeting the JNK pathway for therapeutic benefit.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12769633     DOI: 10.2174/1568007023339472

Source DB:  PubMed          Journal:  Curr Drug Targets CNS Neurol Disord        ISSN: 1568-007X


  18 in total

Review 1.  Roles of amyloid precursor protein family members in neuroprotection, stress signaling and aging.

Authors:  Donat Kögel; Thomas Deller; Christian Behl
Journal:  Exp Brain Res       Date:  2011-11-16       Impact factor: 1.972

Review 2.  Neuroprotective strategies in Alzheimer's disease.

Authors:  Frank M Longo; Stephen M Massa
Journal:  NeuroRx       Date:  2004-01

3.  c-Jun N-terminal kinase inhibitor SP600125 modulates the period of mammalian circadian rhythms.

Authors:  M Chansard; P Molyneux; K Nomura; M E Harrington; C Fukuhara
Journal:  Neuroscience       Date:  2007-01-30       Impact factor: 3.590

4.  Constitutively active cytoplasmic c-Jun N-terminal kinase 1 is a dominant regulator of dendritic architecture: role of microtubule-associated protein 2 as an effector.

Authors:  Benny Björkblom; Nina Ostman; Vesa Hongisto; Vladislav Komarovski; Jan-Jonas Filén; Tuula A Nyman; Tuula Kallunki; Michael J Courtney; Eleanor T Coffey
Journal:  J Neurosci       Date:  2005-07-06       Impact factor: 6.167

Review 5.  Non-'classical' MEKs: A review of MEK3-7 inhibitors.

Authors:  Ada J Kwong; Karl A Scheidt
Journal:  Bioorg Med Chem Lett       Date:  2020-04-23       Impact factor: 2.823

6.  MicroRNA-144 is regulated by activator protein-1 (AP-1) and decreases expression of Alzheimer disease-related a disintegrin and metalloprotease 10 (ADAM10).

Authors:  Cong Cheng; Weiguang Li; Zheng Zhang; Shohei Yoshimura; Qinyu Hao; Chi Zhang; Zhao Wang
Journal:  J Biol Chem       Date:  2013-04-01       Impact factor: 5.157

7.  Neuron specific toxicity of oligomeric amyloid-β: role for JUN-kinase and oxidative stress.

Authors:  Philip J Ebenezer; Adam M Weidner; Harry LeVine; William R Markesbery; M Paul Murphy; Le Zhang; Kalavathi Dasuri; Sun Ok Fernandez-Kim; Annadora J Bruce-Keller; Elena Gavilán; Jeffrey N Keller
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

8.  Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation.

Authors:  Delphine Charvin; Peter Vanhoutte; Christiane Pagès; Emilliana Borrelli; Emiliana Borelli; Jocelyne Caboche
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-15       Impact factor: 11.205

9.  Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125.

Authors:  Yong-Seok Heo; Su-Kyoung Kim; Chang Il Seo; Young Kwan Kim; Byung-Je Sung; Hye Shin Lee; Jae Il Lee; Sam-Yong Park; Jin Hwan Kim; Kwang Yeon Hwang; Young-Lan Hyun; Young Ho Jeon; Seonggu Ro; Joong Myung Cho; Tae Gyu Lee; Chul-Hak Yang
Journal:  EMBO J       Date:  2004-05-13       Impact factor: 11.598

10.  Specific JNK inhibition by D-JNKI1 protects Purkinje cells from cell death in Lurcher mutant mouse.

Authors:  Mariaelena Repici; Hadi S Zanjani; Vanessa Gautheron; Tiziana Borsello; Isabelle Dusart; Jean Mariani
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.